Zentiva has received Global Generics Biosimilars Bulletin Award category EMEA

PRAGUE, Zentiva has acquired the 2020 Global Generics & Biosimilars Bulletin Award in the class of EMEA Acquisition of the year. In Q2 2020, at some point of the height of the first wave of the COVID-19 crisis,  Zentiva executed the acquisition of  Alvogen CEE that added collectively two of the main branded standard and OTC corporations in the CEE region. This acquisition is already displaying warning signs of success and is aiding the trip of Zentiva and its robust ambition to develop whilst enlarging the industrial footprint of the company.


"Zentiva is honored to obtain this prestigious award and recognition. The aggregate of Alvogen and Zentiva in CEE creates a new branded generic, authentic company and OTC powerhouse in the region. The new mixed group is talented, quickly shifting and formidable to force increase from in-house product trends and from strategic partnerships with main corporations that desire to interact Zentiva as a depended on and excessive performing commercialization partner," stated Nick Haggar, Chief Executive Officer, Zentiva. 

Post a Comment